IP Library Granted Patent US 10,232,054
Granted Patent B2
US 10,232,054 · App. 15/118,407 · Granted Mar 19, 2019

Composition for mRNA delivery

Inventors: Kazunori Kataoka (Tokyo, JP); Keiji Itaka (Tokyo, JP); Takehiko Ishii (Tokyo, JP); Hirokuni Uchida (Tokyo, JP); Satoshi Uchida (Tokyo, JP); Miyuki Baba (Tokyo, JP)
Assignee: AccuRna, Inc.
A61K48/0041A61K9/0019A61K9/1075A61K31/7105A61K31/7115A61K38/1761A61K38/18A61K38/185A61K47/10A61K47/34C12N15/87
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,232,054
App. No.
15/118,407
Granted
Mar 19, 2019
Kind
B2
Abstract

A polyion complex of mRNA and a polycationic polymer, and a composition and a pharmaceutical composition for mRNA delivery are provided. The polyion complex of mRNA and the polycationic polymer can deliver mRNA into cells in the body of a subject almost without inducing inflammation. The polyion complex can then cause mRNA to be uniformly expressed in cells in the body of the subject. The pharmaceutical composition containing the polyion complex is suitable for use in treating a disease whose condition rapidly progresses or an acute disease.

Claims (37)

1. A polyion complex comprising a cationic polymer and a messenger RNA (mRNA),

wherein the cationic polymer is a polycation block of formula (I):

wherein

R 1 is a hydroxyl group, a protective group, or a polymerizable group;

R 4 is H, a protective group, a hydrophobic group, or a polymerizable group;

R 2 is methylene;

R 3 is a group represented by —(NH—(CH 2 ) 2 ) p —NH 2 ;

X is any one amino acid selected from cationic natural amino acids;

p is any integer of 1 to 5;

n is any integer of 2 to 5,000;

n 1 is any integer of 0 to 5,000;

n 3 is any integer of 0 to 5,000;

n-n 1 -n 3 is an integer of 0 or more,

although the repeating units in the formula are shown in the particular order for the purpose of description, the repeating units can be present in any order; the repeating units may be randomly present; and the repeating units may be the same or different,

wherein when the polycation block forms a copolymer with polyethylene glycol, R 1 or R 4 represents a bond and polyethylene glycol forms a copolymer with the polycationic block through R 1 or R 4 as the bond;

wherein n-n 1 -n 3 or n 1 is an integer of 2 or more.

2. The polyion complex according to claim 1 , wherein the polycation block is a polycation block of formula (II):

wherein

R1 is a hydroxyl group, a protective group, or a polymerizable group;

R4 is H, a protective group, a hydrophobic group, or a polymerizable group;

R2 is methylene;

R3 is a group represented by —(NH—(CH2)2)p-NH2;

p is any integer of 1 to 5;

q is any integer of 1 to 5;

n is any integer of 2 to 5,000;

n1 is any integer of 0 to 5,000;

n2 is any integer of 0 to 5,000;

n-n1-n2 is an integer of 0 or more,

although the repeating units in the formula are shown in the particular order for the purpose of description, the repeating units can be present in any order; the repeating units may be randomly present; and the repeating units may be the same or different,

wherein when the polycation block forms a copolymer with polyethylene glycol, R1 or R4 represents a bond and polyethylene glycol forms a copolymer with the polycation block through R1 or R4 as the bond.

3. The polyion complex according to claim 1 , wherein the mRNA is an mRNA encoding a growth factor, a cell growth factor, a cytostatic factor, a cell death promoter, a cell death suppressor, a tumor-suppressor gene product, or a transcription factor.

4. The polyion complex according to claim 3 , wherein the cell growth factor is a hemopoietic factor or a brain-derived neurotrophic factor (BDNF).

5. The polyion complex according to claim 3 , wherein the cell death suppressor is Bcl-2.

6. The polyion complex according to claim 1 , wherein the mRNA comprises modified cytidine and uridine.

7. A method for delivering mRNA to the cytoplasm of a cell in the body of a subject, comprising administering the polyion complex according to claim 1 to a subject, wherein the mRNA is delivered to the cytoplasm of the cell.

8. The method according to claim 7 for uniformly expressing a protein in a tissue of a subject or portion thereof in the subject, comprising administering the polyion complex to the subject, wherein the tissue of the subject or portion thereof is perfused with the polyion complex.

9. The method according to claim 8 , wherein the tissue is hepatic or mucosal tissue.

Assignments (6)
CHANGE OF NAME Recorded Sep 10, 2024
From: NANOCARRIER CO., LTD.
To: NANO MRNA CO., LTD.
Reel/Frame 068906/0705 →
CHANGE OF ADDRESS Recorded Sep 10, 2024
From: NANO MRNA CO., LTD.
To: NANO MRNA CO., LTD.
Reel/Frame 068906/0758 →
MERGER Recorded Oct 23, 2020
From: ACCURNA, INC.
To: NANOCARRIER CO., LTD.
Reel/Frame 054224/0106 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2016
From: KATAOKA, KAZUNORI; ITAKA, KEIJI; ISHII, TAKEHIKO; UCHIDA, HIROKUNI; UCHIDA, SATOSHI; BABA, MIYUKI
To: MEDICAL INDUSTRY INNOVATION INSTITUTE
Reel/Frame 039981/0234 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2016
From: MEDICAL INDUSTRY INNOVATION INSTITUTE
To: ITAKA, KEIJI
Reel/Frame 039981/0299 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2016
From: ITAKA, KEIJI
To: ACCURNA, INC.
Reel/Frame 039981/0324 →
Continuity (1)
Related Publication 20170173182A1 · Jun 22, 2017
Cited By (1)
US 12,582,669